Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$155.04 USD

155.04
7,145,777

-0.43 (-0.28%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $158.55, marking a -0.21% move from the previous day.

Sheraz Mian headshot

Top Analyst Reports for Johnson & Johnson, T-Mobile & Caterpillar

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), T-Mobile US, Inc. (TMUS) and Caterpillar Inc. (CAT).

J&J's (JNJ) Bladder Cancer Drug Gets FDA's Breakthrough Tag

FDA grants Breakthrough Therapy Designation to J&J's (JNJ) TAR-200 for high-risk non-muscle-invasive bladder cancer based on data from the phase IIb SunRISe-1 study.

Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca

Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.

The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer

AbbVie, J&J, Eli Lilly, Pfizer are included in this Analyst Blog.

Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $152.11, denoting a +0.32% change from the preceding trading day.

Kinjel Shah headshot

4 Large Drug Stocks to Watch as IBD Market Gains Traction

As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Should Vanguard Russell 1000 Value ETF (VONV) Be on Your Investing Radar?

Style Box ETF report for VONV

Kinjel Shah headshot

Pharma Stock Roundup: NVO & LLY to Expand Manufacturing Capacity in Europe, & More

Eli Lilly (LLY) plans to build a $2.5 billion manufacturing plant in Germany. Novo Nordisk (NVO) plans to invest $2.3 billion to expand an existing production site in France.

The Zacks Analyst Blog Highlights Novo Nordisk Bank of America, Netflix, Johnson & Johnson and TotalEnergies

Novo Nordisk, Bank of America, Netflix, Johnson & Johnson and TotalEnergies are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Novo Nordisk, Bank of America & Netflix

Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Bank of America Corporation (BAC) and Netflix, Inc. (NFLX).

J&J (JNJ) Seeks Expanded Use of Lung Cancer Drug Rybrevant

J&J's (JNJ) sBLA seeks label expansion for Rybrevant plus chemotherapy to treat patients with EGFR-mutated NSCLC whose disease progressed on or after treatment with AstraZeneca's Tagrisso (osimertinib).

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

Sector ETF report for IYH

Andrew Rocco headshot

13F Rundown: Tepper, Buffett, Druckenmiller

Stock Strategist Andrew Rocco divulges valuable insights from the world's best and brightest investors.

Should Vanguard High Dividend Yield ETF (VYM) Be on Your Investing Radar?

Style Box ETF report for VYM

Johnson & Johnson (JNJ) Down 2.6% Since Last Earnings Report: Can It Rebound?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, J&J and AbbVie

Eli Lilly, Novo Nordisk, J&J and AbbVie are part of the Zacks Industry Outlook article.

Kinjel Shah headshot

4 Large Drug Stocks Likely to Sail Through Industry Woes

Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), J&J (JNJ) and AbbVie (ABBV) are worth retaining in your portfolio.

Should You Invest in the Vanguard Health Care ETF (VHT)?

Sector ETF report for VHT

Bayer's (BAYRY) Q3 Earnings and Revenues Miss Estimates

Bayer (BAYRY) reports weaker-than-expected third-quarter 2023 results. Management maintains its 2023 outlook.

Halozyme (HALO) Q3 Earnings Top Estimates, Revenues Lag

Halozyme's (HALO) third-quarter earnings beat estimates, while revenues miss the same. The company maintains revenue guidance for full-year 2023.

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.